Identifying potentially disruptive biopharmaceutical companies within a sea of less compelling opportunities

The Rapha Capital Mission is to use our unique abilities to identify at the earliest stage, those companies that we believe will go on to profoundly improve peoples’ lives while building great value, from a sea of seemingly indistinguishable, less compelling, opportunities.

Rapha Capital Management is focused on identifying and growing revolutionary ideas in medicine, healthcare and technology before others can see their value.

Rapha Capital Management, LLC, founded in mid-2018, has grown to include 13 managed entities, Rapha Capital Investment I – XIII.

Poseida Therapeutics Logo

Poseida Therapeutics, Inc.

NexImmune Icon

NexImmune, Inc.

Rapha Capital Latest News


July 27, 2023 in Asclepix Therapeutics, Inc., Rapha Capital Management

AsclepiX Therapeutics Raises $10 Million to Advance Phase 1/2a Clinical Study of AXT107

Perceptive Advisors leads round to execute study in patients with wet age-related macular degeneration (wet AMD)BALTIMORE, MD, July 26, 2023– AsclepiX…
Read More
December 7, 2022 in 3DBio Therapeutics, Inc., Portfolio, Rapha Capital Management

Popular Science Magazine Names 3D Bio Therapeutics “Best of What’s New – 2022” Grand Award Winner in Health for AuriNovo™

– 3D Bio is the first company implanting 3D-bioprinted living tissues in patients – – Rapha Capital Management, LLC has…
Read More
August 22, 2022 in IMAGIN Medical, Portfolio, Rapha Capital Management

Imagin Medical Announces Acquisition of the enCAGE Coil™ Precision Ablation System for Prostate Cancer and a New $7.25M Convertible Note to Finance Its Development

Rapha Capital BioVentures Fund I, LP (Rapha Capital), and Bigger Capital lead the financing. VANCOUVER, BC, and BOSTON, MA, August…
Read More